Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Rudolf A de BoerJulio NúñezPlamen KozlovskiYi WangPieter ProotDeborah KeefePublished in: British journal of clinical pharmacology (2020)
The reduction in NT-proBNP with licogliflozin suggests a potential benefit of SGLT1 and 2 inhibition in patients with T2DM and heart failure.